Aldeyra Therapeutics (ALDX) finance chief buys 5,000 shares

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. Principal Financial Officer Michael Alfieri reported an open-market purchase of common stock. On this transaction date, he bought 5,000 shares at a price of $1.42 per share. Following the purchase, his direct ownership increased to 7,500 common shares.

Insider Trade Summary

Net Buyer: 5,000 shares ($7,100)

Net Buy 1 txn

Insider Alfieri Michael

Role Principal Financial Officer

Bought 5,000 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$1.42	$7K

Holdings After Transaction: Common Stock — 7,500 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alfieri Michael

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		P		5,000	A	$1.42	7,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Alfieri	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aldeyra Therapeutics (ALDX) report in this Form 4?

Aldeyra Therapeutics reported that Principal Financial Officer Michael Alfieri made an open-market purchase of common stock. He bought 5,000 Aldeyra common shares, increasing his direct holdings to 7,500 shares after the transaction, according to the Form 4 filing data.

How many Aldeyra Therapeutics (ALDX) shares did Michael Alfieri buy and at what price?

Michael Alfieri purchased 5,000 shares of Aldeyra Therapeutics common stock in an open-market transaction. The reported purchase price was $1.42 per share, as disclosed in the Form 4 insider filing for this transaction.

What is Michael Alfieri’s total Aldeyra Therapeutics (ALDX) shareholding after this trade?

After the reported insider purchase, Michael Alfieri directly owns 7,500 shares of Aldeyra Therapeutics common stock. This total reflects his holdings immediately following the 5,000-share open-market buy disclosed in the Form 4.

What role does Michael Alfieri hold at Aldeyra Therapeutics (ALDX)?

Michael Alfieri serves as the Principal Financial Officer of Aldeyra Therapeutics. His position means he is a key financial executive, and his equity transactions in company stock are required to be disclosed through Form 4 insider filings with the SEC.

Was the Aldeyra Therapeutics (ALDX) insider transaction a buy or a sell?

The reported insider transaction was a buy. The Form 4 classifies it as an open-market purchase, with Michael Alfieri acquiring 5,000 Aldeyra Therapeutics common shares and increasing his directly held position to 7,500 shares.